Isuprel

Quick links to important sections

Isuprel

Method of action: Cardiac Therapy

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isuprel

What is Isuprel? An Overview

Property Description
Active Ingredient Isoprenaline Hydrochloride (Isoproterenol)
Form Sterile Solution, Metered-dose Inhaler, Sublingual Tablet
Pharmacological Class Non-selective beta-Adrenergic Agonist
General Purpose Cardiac stimulation and Bronchodilation
Origin Synthetic

What is Isuprel (Isoprenaline)?

Isuprel is the original trade name for the powerful, synthetic medication whose active ingredient is Isoprenaline Hydrochloride, also known as Isoproterenol (the International Nonproprietary Name, or INN). This medication is a single-ingredient product and is clinically recognized for its critical role in immediate medical intervention. Isuprel is distinguished by its primary administration as a sterile solution for injection or intravenous infusion, which underscores its established use in acute circulatory emergencies.

What Type of Medicine is Isoprenaline?

Isoprenaline belongs to the Sympathomimetic Amine class, making it a type of Catecholamine that mimics the action of natural stress hormones. It is formally categorized as a non-selective beta-Adrenergic Agonist because it simultaneously activates both beta1 receptors in the heart and beta2 receptors in the airways. This dual action is critical, allowing Isoprenaline to influence both cardiac rate and respiratory function. The drug's synthetic origin ensures purity and consistency, a vital factor in its use for severe conditions like acute heart block or severe, persistent bronchospasm.

What are the Preparations and General Purpose of Isuprel?

Isuprel is available in multiple dosage forms, predominantly as a sterile solution for injection or intravenous infusion for immediate systemic action, but also as a metered-dose inhaler and sublingual tablets. The general purpose of Isoprenaline is to rapidly correct physiological instability by providing essential cardiorespiratory support. It achieves this by directly increasing the rate and force of the heart’s contractions and promoting immediate relaxation and widening of constricted airways (bronchodilation).

What side effects are possible with Isuprel?

Possible Side Effects and Safety Information: Isuprel

The safety profile of Isoprenaline (Isuprel), a potent non-selective beta-adrenergic agonist, is primarily defined by its effects on the cardiovascular and nervous systems, as documented in official government regulatory information.


Frequency and System-Organ Classes

The most commonly reported adverse reactions are generally transient and are related to the drug's acute sympathomimetic action. The following effects are typically classified as Common in regulatory documents:

  • Cardiac Disorders: Tachycardia (fast heart rate) and Palpitations.
  • Nervous System Disorders: Headache and Tremor.

Less frequently reported or with frequency Not Known are reactions such as Nausea, Vomiting, Nervousness, Dizziness, Sweating, and changes in blood pressure (Hypotension or Hypertension).


Serious Adverse Reactions and Safety Constraints

Official labeling defines several serious adverse reactions associated with Isoprenaline use. The most critical risk is the induction of Ventricular Arrhythmias (including ventricular tachycardia or fibrillation) and the exacerbation of Angina Pectoris or Myocardial Ischemia in susceptible patients. These effects are often dose-dependent, with regulatory text advising caution when the heart rate exceeds 130 beats per minute.

Safety constraints prohibit the use of Isoprenaline in individuals with pre-existing conditions such as Tachyarrhythmias, Ventricular Arrhythmias, Angina Pectoris, or heart block caused by Digitalis intoxication. Furthermore, the presence of sodium metabisulfite in the solution has led to warnings regarding the risk of allergic-type reactions, including anaphylaxis, particularly in individuals with asthma. Use requires continuous physiological monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the official, regulator-documented manifestations of Isuprel (Isoprenaline) overdose and the mandated emergency actions.

Overdosage is primarily characterized by an exaggeration of the drug's cardiovascular effects.


Documented Manifestations and Severe Outcomes

Category Officially Documented Manifestations
Cardiovascular Signs Tachycardia (rapid heart rate), Palpitations, Angina (chest pain), Arrhythmias, Hypotension, Hypertension
Systemic/CNS Symptoms Nervousness, Headache, Dizziness, Mild Tremors

Excessive doses may result in severe outcomes, including myocardial ischemia (inadequate blood supply to the heart muscle) and the precipitation of ventricular arrhythmias. Official labeling warns that repeated large doses may lead to cardiac enlargement and focal myocarditis.

In the pediatric population, high-rate intravenous infusions have been associated with myocardial necrosis and death.


Official Emergency Actions

In cases of suspected overdosage, the required action is to reduce the rate of administration or discontinue the Isuprel infusion until the patient's condition stabilizes. Urgent medical attention is necessary, particularly if the heart rate exceeds 110 beats per minute, which may advise temporary discontinuation.

Treatment consists of symptomatic and supportive measures. Continuous monitoring of blood pressure, respiration, and the electrocardiogram (EKG) is required. The prescribing information confirms that no specific antidote is known for Isoproterenol overdose.

Therapeutic Uses of Isuprel

Main Uses of Isuprel

Isuprel is a medication primarily used to manage specific cardiovascular and respiratory conditions. It contains the active ingredient isoproterenol hydrochloride, a potent beta-adrenergic agonist that acts on the heart and the bronchial tubes.

Cardiovascular Applications

Isuprel is utilized in various clinical settings to address heart-related issues, particularly those involving the electrical conduction system and heart rate. Its primary cardiovascular uses include:

  • Heart Block: It is used as a temporary measure to manage certain types of heart block, a condition where the electrical signals that tell the heart to beat are delayed or blocked.
  • Cardiac Arrest: In emergency situations, it may be administered to stimulate the heart's activity during cardiac arrest until more definitive treatments, such as a pacemaker or defibrillation, can be applied.
  • Shock: It is sometimes used in the treatment of shock states, such as cardiogenic shock or septic shock, where it helps increase the volume of blood pumped by the heart (cardiac output) to maintain circulation to vital organs.
  • Bradycardia: The medication is effective in treating severe, symptomatic bradycardia (an abnormally slow heart rate) that has not responded to other initial treatments.

Respiratory Applications

In addition to its cardiac effects, Isuprel has properties that affect the lungs. Historically and in specific clinical scenarios, it is used for:

  • Bronchospasm: It acts as a bronchodilator to relieve airway constriction during anesthesia or in other acute respiratory distress situations. By relaxing the muscles in the airways, it helps improve airflow and ease breathing.

Benefits of Isuprel

The primary benefit of Isuprel lies in its rapid onset of action and its ability to provide immediate support to the circulatory and respiratory systems.

Increased Cardiac Performance

By stimulating beta-1 receptors in the heart, Isuprel increases both the strength of the heart's contractions and the rate at which it beats. This dual action is beneficial in critical care settings where restoring adequate blood flow is essential for patient stabilization.

Improved Airway Conductivity

Through its action on beta-2 receptors in the lungs, the medication provides rapid relief from bronchial constriction. This helps restore normal breathing patterns in patients experiencing acute respiratory compromise.

Versatility in Emergency Medicine

Isuprel serves as a vital bridge therapy. Its ability to support the heart and lungs quickly makes it a valuable tool for stabilizing patients while healthcare providers prepare for long-term interventions, such as the surgical implantation of a permanent pacemaker or the management of underlying systemic infections.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Isuprel (Isoproterenol)

The use of Isuprel is strictly defined by regulatory authorities and is determined largely by pre-existing cardiac status and age-group limitations.

Category Official Regulatory Status
Populations for whom use is allowed Acute, short-term use in adults for specific cardiac conditions or bronchospasm.
Populations for whom use is contraindicated Patients with tachyarrhythmias, angina pectoris, ventricular arrhythmias requiring inotropic therapy, or heart block caused by digitalis intoxication.
Age-related eligibility rules Pediatric Use: Safety and efficacy have not been established. Geriatric Use: Dose selection must be cautious due to the greater frequency of decreased organ function.
Condition-specific eligibility rules Caution required in patients with coronary artery disease, hyperthyroidism, or diabetes mellitus. Sulfite sensitivity requires caution due to the injectable formulation's components.
Pregnancy and lactation eligibility status Pregnancy: Use only if clearly needed. Lactation: Caution should be exercised as it is unknown if the drug is excreted in human milk.

These statements define the official eligibility profile, prohibiting use in unstable cardiac states and requiring restricted use for populations with specific comorbidities or insufficient safety data.

What should I know about interactions with other medicines?

Isoprenaline's official interaction profile is structured around both pharmacodynamic and pharmacokinetic effects documented in regulatory labeling. The interactions are classified to ensure proper administration constraints based on official governmental documentation.

Contraindicated Combinations and Major Restrictions

Co-administration is formally contraindicated or restricted with several substance categories. Monoamine Oxidase Inhibitors (MAOIs) are restricted due to the combined effect of metabolism reduction and pharmacodynamic synergism, which carries a risk of acute hypertensive episodes. Epinephrine (Adrenaline) must not be administered simultaneously due to the potential to induce serious arrhythmias; alternate administration requires a proper interval. Use with Halogenated Inhalational Anesthetics is restricted because they may sensitize the myocardium, increasing the risk of ventricular arrhythmias. Co-administration with Cardioactive Glycosides is also restricted as combined effects may induce serious arrhythmias.

Exposure-Modifying and Pharmacodynamic Interactions

COMT Inhibitors are officially documented to inhibit Isoprenaline metabolism, leading to an increase in systemic exposure and a heightened risk of cardiodynamic effects. Beta-Adrenergic Blocking Drugs are documented to cause pharmacodynamic antagonism, reducing the intended effect of Isoprenaline. Tricyclic Antidepressants (TCAs) may potentiate clinical response, increasing the risk of severe, prolonged hypertension. Additionally, there are population-specific interaction notes: co-administration with Corticosteroids and Methylxanthines in Pediatric Refractory Asthma carries documented risks of cardiac toxicity.

Mechanism of Action

How Isuprel Works

Isuprel (isoproterenol) functions as a synthetic sympathomimetic amine, acting as a non-selective agonist at both beta1 and beta2 adrenergic receptors. Binding to these receptors initiates an intracellular signaling cascade mediated by the Gs protein, leading to increased synthesis of cyclic AMP (cAMP) within the target cells.

Activation of beta1 receptors in the cardiac conduction system—the sinoatrial and atrioventricular nodes—increases the slope of phase 4 depolarization by modulating L-type calcium channel function. This results in positive chronotropy (increased heart rate) and positive dromotropy (accelerated conduction velocity), alongside increased force of contraction (positive inotropy).

Simultaneously, activation of beta2 receptors on vascular and bronchial smooth muscle leads to the inactivation of myosin light chain kinase. This molecular change prevents actin-myosin cross-bridge formation, inducing smooth muscle relaxation. The physiological consequence is a decrease in peripheral vascular resistance and widening of the bronchial passages, influencing systemic blood flow dynamics.

Dosage and Administration Information

Isuprel (isoproterenol hydrochloride) injection is administered only in acute, controlled settings, such as a hospital, using the parenteral route (intravenous infusion, bolus intravenous, intramuscular, subcutaneous, or intracardiac injection).

Official Administration Guidelines

Clinical Context Route of Administration Preparation Requirement Initial Adult Dosing
Shock/Hypoperfusion Intravenous Infusion Dilute 5 mL (1 mg) in 500 mL of 5% Dextrose Injection, USP. 0.5 mcg to 5 mcg per minute.
Bronchospasm (During Anesthesia) Bolus Intravenous Injection Dilute 1 mL (0.2 mg) to 10 mL with Sodium Chloride or 5% Dextrose Injection, USP. 10 mcg to 20 mcg.

Procedural and Monitoring Requirements

Administration must begin at the lowest recommended dose and be increased gradually while the patient is carefully monitored. The dosage is adjusted based on the patient's response, including heart rate, systemic blood pressure, and urine flow. If the heart rate exceeds 110 beats per minute, the infusion rate should be decreased or temporarily discontinued.

Prior to dilution, the solution must be visually inspected for particulate matter or discoloration. The product must not be used if it appears pinkish or darker than slightly yellow, or if it contains a precipitate. Any diluted solution should be used immediately and the unused portion must be discarded.

Age-Specific Notes

No well-controlled studies have established appropriate dosing for pediatric patients. For geriatric patients, dose selection should be cautious, typically starting at the lower end of the dosing range, due to the greater frequency of decreased organ function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Isuprel

Evidence for Use in Slow Heart Rhythms (Bradyarrhythmias)

Isuprel (Isoprenaline) was evaluated in research exploring conditions associated with a critically slow heart rate and certain types of heart block. Research in this area includes a limited number of small-scale Randomized Controlled Trials (RCTs) and physiological analyses that research examined in acute care settings. These studies monitored outcomes related to systemic or functional imbalance by measuring the immediate effect on the heart's rate and its electrical conduction system.

Findings indicate that research highlights measured changes in the heart's speed and electrical activity following administration. Reported outcomes were short-term (minutes to hours), concentrating only on the immediate physiological response in adult patients. The drug's historical use precedes the wide adoption of selective medications and medical devices, meaning data are still emerging regarding its current use relative to modern standards.


Evidence for Use in Acute Circulatory Support (Shock)

Research has explored patterns of response to Isuprel in conditions associated with circulatory failure (shock) where the heart's pumping ability is significantly reduced. The evidence base primarily consists of observational studies and acute physiological research conducted in critical care settings. These studies monitored outcomes related to physiological strain or stress, specifically assessing key hemodynamic parameters like cardiac output and blood pressure.

In these observational settings, research describes patterns of short-term shifts in physiological measurements, such as cardiac output, in critically ill adult patients. The studies often included highly specific patient groups, such as those with certain shock etiologies or patients with specific complications following heart transplant. Follow-up durations were limited to the immediate critical care stay.


Limitations and Research Uncertainty

The overall research landscape for Isuprel includes characteristics such as modest sample sizes and limited follow-up duration in many of the formal clinical trials. The evidence quality varies across studies, with many relying on observational data rather than large-scale, modern RCTs. This means research provides context but not individual predictions. Long-term outcomes are not well characterized, and data for certain groups, including older adults with complex comorbidities, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Isuprel (FAQ)


Q: What are the major side effects associated with Isuprel that patients ask about most?

A: According to official product information, the most frequently reported adverse reactions are generally related to the drug's acute stimulating effects. These effects are typically classified in regulatory documents as Common, and include tachycardia (fast heart rate), palpitations (a fluttering or pounding feeling in the chest), headache, and tremor (shaking).


Q: Can Isuprel cause a feeling of a racing heart or palpitations?

A: Yes, regulatory documents list tachycardia (a fast heart rate) and palpitations as common adverse reactions. These effects are related to how the drug works on the heart and are closely monitored by the medical team during administration.


Q: Is a headache a common side effect when getting Isuprel?

A: Yes, headache is listed among the commonly reported adverse reactions in official regulatory information. As a common temporary effect, it is typically managed as part of the overall patient monitoring plan.


Q: What safety precautions are listed for patients with kidney problems using Isuprel?

A: While specific precautions for patients with severe kidney problems are often individualized, official information for older adults advises caution due to potential decreased organ function. General guidance suggests that lower doses may be appropriate for initial therapy.


Q: What specific conditions must be corrected before Isuprel is started?

A: Official warnings emphasize that attention should be paid to conditions such as the patient's acid-base balance and the correction of electrolyte disturbances. Additionally, the drug is formally contraindicated (not to be used) in patients with conditions such as pre-existing tachyarrhythmias (very fast heart rhythms).


Q: Is there a known interaction between Isuprel and anesthetics used in surgery?

A: Yes, the product label specifically restricts use with Halogenated Inhalational Anesthetics (a type of gas used for general anesthesia). This is because combining these substances may sensitize the heart muscle and increase the risk of serious ventricular arrhythmias (dangerous irregular heartbeats).


Q: Can taking cold medicine or decongestants interfere with Isuprel?

A: Official information indicates that the effects of Isuprel may be increased by certain classes of drugs, including some antihistamines and other sympathomimetic agents. These are often ingredients found in common cold or decongestant medicines, and their concurrent use may require monitoring.


Q: What is the difference between Isuprel's effects on the heart and its effects on the lungs?

A: Isuprel works as a non-selective beta-adrenergic agonist. This means it activates beta1 receptors in the heart to increase the heart rate and force of contraction, while simultaneously activating beta2 receptors in the lungs to cause smooth muscle relaxation, which leads to the widening of air passages (bronchodilation).


Q: Is it possible to be allergic to the ingredients in Isuprel?

A: Yes, the injection solution contains sodium metabisulfite, a non-drug component that is noted in regulatory text for potentially causing mild to severe allergic-type reactions. This includes serious reactions like anaphylaxis, particularly in individuals with a known history of allergies or asthma.


Q: Are there any non-drug components in the Isuprel injection that can cause reactions?

A: Yes, the preservative sodium metabisulfite is a non-drug component that is highlighted in regulatory text as being associated with the risk of allergic-type reactions in sensitive individuals.


Q: What should a family member watch out for when a patient is receiving Isuprel?

A: The medical team is required to continuously monitor the patient's condition, including their heart rate and blood pressure. Family members may be advised to observe for signs of serious adverse reactions noted in official warnings, such as a severe racing or pounding heartbeat, new or worsening chest pain, or a severe headache.


Q: Is Isuprel the same type of drug as epinephrine or dopamine?

A: Chemically, Isoproterenol is classified as a synthetic catecholamine derivative. Official information describes it as the N-isopropyl analogue of naturally occurring epinephrine (adrenaline) and norepinephrine, meaning they are very similar in structure and function.


Q: How quickly is Isuprel supposed to start working?

A: When administered by the intravenous (IV) route, the drug is generally described in official sources as having an immediate onset of action.


Q: How long does the effect of Isuprel usually last after it's stopped?

A: The duration of effect for the intravenous (IV) administration route is typically described in authoritative sources as being approximately 10 to 15 minutes.


Q: Is Isuprel ever used outside of critical care or emergency settings?

A: Official indications limit its use to specific, acute medical interventions. These include managing certain heart rate conditions, improving circulatory status in shock, and treating bronchospasm occurring during anesthesia, which are generally controlled, critical care settings.


Q: Is it true that Isuprel is only a temporary fix for heart issues?

A: Official documents describe its use for acute medical interventions. The clinical research that supports its use primarily focuses on short-term outcomes, indicating it is generally used for a limited duration to stabilize physiological function.


Q: Are there any long-term effects of having received Isuprel?

A: Regulatory documents state that long-term outcomes are not well characterized in human studies. The evidence primarily focuses on the immediate physiological response during acute care, and no long-term studies to evaluate carcinogenic potential in animals have been conducted.


Q: Can Isuprel affect sleep or cause insomnia?

A: Yes, official regulatory documents list insomnia (difficulty sleeping) as an adverse reaction in the nervous system/psychiatric category.


Q: Does Isuprel require special mixing or preparation before administration?

A: Yes, for both intravenous infusion and bolus injection, the sterile solution must be diluted using specific materials like Sodium Chloride Injection or 5% Dextrose Injection, USP before it can be administered to a patient.


Q: Are there foods or drinks that need to be avoided while receiving Isuprel?

A: While formal food contraindications are not consistently listed in major regulatory labels, official information notes one documented alcohol/food interaction that requires clinical monitoring. Specific dietary restrictions are addressed within the comprehensive patient care plan.


Q: Is Isuprel safe for use in children?

A: Official labeling states that the safety and efficacy have not been established in pediatric patients. However, authoritative medical groups have provided guidelines for its monitored use in this population.


Q: Why is Isuprel classified as a high-alert medication?

A: Isoproterenol is classified by organizations like the Institute for Safe Medication Practices (ISMP) as a High-Alert medication because it carries an increased risk of causing significant patient harm if the medication is used incorrectly.


Q: How does the use of Isuprel relate to pacemaker placement?

A: The drug is indicated to treat specific conditions like heart block (a disruption of the heart's electrical system). In some cases, it may be used to manage this condition to stabilize the patient prior to the insertion of a permanent pacemaker.


Q: What is the difference between Isuprel and other similar 'pressor' drugs?

A: Isoproterenol is distinguished as a non-selective beta-adrenergic agonist. This means that unlike some other 'pressor' drugs that target alpha receptors (mainly causing vasoconstriction), Isuprel's effects are primarily concentrated on the beta receptors, causing both cardiac stimulation and vasodilation.


Q: Is Isuprel used to treat low blood pressure (hypotension)?

A: The drug is officially indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. These clinical states are often characterized by severe low blood pressure, and the drug aims to restore circulation by improving heart function.


Q: Does Isuprel increase the heart's need for oxygen?

A: Yes, caution is advised in the product's official warnings because the drug may increase myocardial oxygen requirements (the amount of oxygen the heart muscle needs). This potential effect is closely monitored to prevent the risk of ischemia (lack of oxygen) in susceptible patients.


Q: Can Isuprel be used for breathing problems or asthma?

A: Yes, one of the official indications listed in regulatory documents is for the treatment of bronchospasm occurring during anesthesia. This effect is due to its ability to relax and widen the bronchial passages.


Q: How is the dose of Isuprel determined by the medical team?

A: The dosage is determined by starting at the lowest recommended dose and increasing gradually while carefully monitoring the patient's immediate response. The medical team uses specific measures like the patient's heart rate, systemic blood pressure, and urine flow to adjust the rate of administration.


Q: Do official documents mention any effects of Isuprel on vision?

A: Yes, official regulatory documents list visual blurring (blurred vision) as an adverse reaction in the nervous system disorders category.


Q: Why is Isuprel sometimes mentioned in discussions about heart transplant procedures?

A: Research evidence includes studies that have explored patterns of response to Isuprel in critically ill patients, specifically including those with specific complications following heart transplant.


Q: Can Isuprel affect blood sugar levels?

A: Official warnings recommend caution for use in patients with diabetes mellitus because the drug has the potential to transiently increase blood glucose levels (blood sugar).

How should Isuprel be stored and disposed of?

Storage and Disposal of Isuprel (Isoproterenol)

The storage conditions for Isuprel (Isoproterenol Hydrochloride) Injection are strictly defined by regulatory labeling to maintain its stability and effectiveness.


Official Storage Requirements

  • Temperature: Store the injection at 20 C to 25 C (68 F to 77 F), which is Controlled Room Temperature.
  • Protection: The product must be protected from light and should be kept in its opaque container until the moment of use.
  • Stability Check: Do not use the solution if it appears pinkish or darker than slightly yellow or if it contains a precipitate.
  • Child Safety: Like all prescription medications, keep Isuprel out of reach of children.

Handling and Disposal

  • Disposal: Any unused portion of the injection must be discarded immediately following administration.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isuprel found in:

A-Z Index: